A significant federal policy adjustment regarding medical marijuana reclassification has been enacted in the United States, impacting state-licensed programs and industry operations. President Donald Trump recently signed an executive order that initiated a shift in the federal classification of medical marijuana products. This action, further solidified by an order signed by acting Attorney General Todd Blanche on April 23, 2026, moves these products from Schedule I to Schedule III under federal drug regulations, as reported by the Mississippi Clarion Ledger.
Federal Reclassification and Regulatory Implications
The reclassification from Schedule I, the highest level of regulation, to Schedule III, a less restrictive category, represents a change in the federal regulatory framework for medical cannabis. Acting Attorney General Blanche stated that this rescheduling “allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
It is important to note that this executive action does not constitute federal legalization of recreational cannabis. The changes specifically downgrade penalties for individuals possessing medical marijuana in a manner that violates federal law. President Trump had also signed an executive order in December, which eased some federal penalties for recreational use, but did not nationalize legalization or override state-specific marijuana laws. The Department of Justice is scheduled to hold an expedited hearing on June 29, 2026, to consider a broader reclassification of marijuana, a push that originated under former President Joe Biden’s administration.
Impact on State Medical Cannabis Programs
The federal medical marijuana reclassification is expected to streamline operations for the medical cannabis industry, particularly by enabling businesses to file federal tax deductions. This change also facilitates research into cannabis’s medical applications.
Mississippi’s Medical Cannabis Program
In Mississippi, medical marijuana is legal for purchase and use through the state’s Medical Cannabis Program. To access medical marijuana, individuals must possess a medical cannabis card issued by the state. Mississippi-registered physicians are authorised to prescribe cannabis for over 20 qualifying conditions, including cancer, glaucoma, and Parkinson’s disease. The Mississippi Medical Cannabis Program maintains a comprehensive list of these conditions.
Operational aspects of the Mississippi program include:
- Patients and caregivers incur fees, and doctor visits are an additional cost.
- Health insurance does not cover medical marijuana expenses.
- Products are sold at approved dispensaries.
- Cardholders are permitted to purchase a maximum of 24 Mississippi Medical Cannabis Equivalency Units (MMCEUs) within a 30-day period and can possess up to 28 MMCEUs at any given time.
Non-residents can also obtain medical marijuana in Mississippi, subject to specific limitations. Temporary medical marijuana cards are available up to twice annually, each valid for 15 days, requiring proof of medical marijuana eligibility from the applicant’s home state. Non-residents may purchase up to 6 MMCEUs per week or 12 per 15-day period. Recreational marijuana remains illegal in Mississippi, though penalties for possessing small amounts have been eased, with consequences varying based on the specific circumstances.
Industry and Research Outlook
The shift to Schedule III is anticipated to reduce regulatory burdens on businesses operating within the medical marijuana sector. The ability for these businesses to claim federal tax deductions, previously unavailable due to cannabis’s Schedule I status, represents a material financial benefit. Furthermore, the less restrictive classification is intended to foster increased scientific research into the safety and efficacy of cannabis, potentially leading to a more robust evidence base for its therapeutic uses.
Public sentiment regarding cannabis legalization varies. A 2025 Gallup poll indicated that 64% of Americans supported the legalization of cannabis. However, the federal reclassification has also drawn opposition from some political figures. Following President Trump’s December executive order, more than 20 Republican senators, including Mississippi’s Cindy Hyde-Smith, sent a letter expressing concerns about the drug’s potential harms and urging a reconsideration of the policy direction.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
